Atomoxetine capsules recalled due to elevated N-nitroso impurity
Glenmark Pharmaceuticals is recalling Atomoxetine 40 mg capsules nationwide due to manufacturing deviations. Some lots contain N-nitroso Atomoxetine impurity above FDA-recommended limits.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: FDA Class II recall with no reported illnesses or injuries. The hazard is chemical contamination—N-nitroso impurity above FDA limits in a prescription pharmaceutical. Scores 3 per rubric criterion for risk-of-harm products where injury has not been reported.
Plain-English summary
Glenmark Pharmaceuticals Inc., USA is recalling Atomoxetine Capsules, USP, 40 mg supplied in 30-capsule bottles. The affected lot numbers are 19234109 (expires 9/2025), 19234897 (expires 11/2025), 19240501 (expires 1/2026), 19241489 (expires 3/2026), and 19241806 (expires 4/2026). Approximately 190,320 bottles have been distributed nationwide within the United States.
The recall was initiated due to current Good Manufacturing Practice (cGMP) deviations. Specifically, testing identified N-Nitroso Atomoxetine impurity in some lots at concentrations exceeding FDA-recommended limits.
Patients currently taking Atomoxetine from affected lots should consult their healthcare provider or pharmacist before taking any action. Do not stop taking medication without medical guidance. Healthcare providers and pharmacists should verify inventory against the recalled lot numbers and expiration dates and quarantine any affected product.
The recalled product
- Product
- ATOMOXETINE (ATOMOXETINE)
- Brand
- ATOMOXETINE
- Manufacturer
- Glenmark Pharmaceuticals Inc., USA
- Category
- Drug
- Hazard
- n-nitroso-impurity
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (10)
- Lot Numbers: 19234109
- Exp.: 9/2025
- 19234897
- Exp.: 11/2025
- 19240501
- Exp.: 1/2026
- 19241489
- Exp.: 3/2026
- 19241806
- Exp.: 4/2026.
UPCs (7)
- 0368462265307
- 0368462270301
- 0368462267301
- 0368462271308
- 0368462268308
- 0368462269305
- 0368462266304
Distribution
Distributed nationwide across the United States.
Related recalls
Same brand · ATOMOXETINE
- SevereAtomoxetine Capsules Recalled Due to Labeling Mix-Up Error
FDA (Drugs) · 2026-05-27
- HighAtomoxetine 80 mg Capsules Recalled for N-Nitroso Impurity Contamination
FDA (Drugs) · 2025-02-26
- HighAtomoxetine Capsules Recalled for N-Nitroso Impurity Above FDA Limits
FDA (Drugs) · 2025-02-26
- HighAtomoxetine Capsules Nationwide Recall for N-Nitroso Impurity Above FDA Limits
FDA (Drugs) · 2025-02-26
- HighAtomoxetine Capsules Recalled for Manufacturing Impurity Above Limits
FDA (Drugs) · 2025-02-26
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27
- LowPrimidone Tablets Recalled for Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27